8 results about "Leukemia cell line" patented technology

The invention belongs to the technical field of biological detection, and provides a multiple cell factor detection kit in macrophage polarization and a preparation method and application thereof, and the detection kit comprises a capture antibody, a detection antibody, a mixed protein standard substance, a diluent and a washing buffer solution. The capture system is used for preparing a capture antibody coupled with a fluorescence coding microsphere by coupling a biotinylated antibody with a fluorescence microsphere coated with biotin, and the detection system is used for preparing a fluorescence labeled antibody by coupling derivatized phycoerythrin PE-SMCC with a specific thioether bond of a sulfhydrylated antibody. The mixed protein standard substance adopts a freeze-drying protection system containing BSA, trehalose and the like. The single hole of the kit can synchronously detect multiple cell factors, the sample dosage is only 25 microliters, the kit is suitable for in-vitro tests of mouse mononuclear macrophage leukemia cell lines RAW264.7, compared with a traditional ELISA method, the efficiency is improved by 10 times, the cost is reduced, and the kit has the remarkable advantages of being high in throughput, wide in linear range and high in stability.

The present invention relates to a novel compound having inhibitory activity against leukemia cell lines and a medical use thereof. The novel compound according to the present invention has excellent inhibitory activity against leukemia cell lines and thus can treat related diseases, and in particular, has an excellent therapeutic effect on acute myeloid leukemia (AML) and thus can be effectively used for treating leukemia as described above.

This invention relates to the field of pharmaceutical technology, specifically to the application of *Citrus aurantium* in the preparation of antitumor drugs. The invention uses *Citrus aurantium* as a raw material to obtain, for the first time, extracts with antitumor activity and novel compounds with extremely high activity. Furthermore, it provides a new natural method for obtaining *Citrus aurantium* alkaloids A, B, C, and D. The extracts and isolated monomeric compounds can effectively inhibit the growth of various tumor cell lines in vitro, including human colorectal cancer cells, human chronic myeloid leukemia cell lines, human gastric adenocarcinoma cell lines, human small cell lung cancer cell lines, and human liver cancer cell lines. The obtained extracts and monomeric compounds target a wide range of cancer cells, exhibiting significant effects on various cancer cells, thus achieving therapeutic effects and showing broad application prospects.

The invention provides a medicine for targeting early-stage precursor T cell acute lymphocytic leukemia (ETP-ALL) and application of the medicine. Dichloroacetic acid (DCA) is used for regulating mitochondrial oxidative phosphorylation, so that electron transport chain flux can be enhanced, ROS (reactive oxygen species) generation can be promoted, endoplasmic reticulum stress related pathways can be activated, the proliferation states of an ETP-ALL leukemia cell line and a primary patient sample can be influenced, and cell apoptosis can be induced. In cell line-derived and patient-derived xenograft models, DCA treatment can reduce leukemia load in bone marrow, spleen and peripheral blood and affect tumor formation characteristics. DCA shows good tolerance in normal hematopoietic system and other leukemia models. The method provides a treatment strategy based on metabolism targeted regulation, and provides a potential technical route and application reference for ETP-ALL research and drug development.

This useful solution refers to a procedure for isolating and purifying the compound kaempterol-3-O-rhamnoside from the bark of the medicinal tree Schima wallichii (DC.) Korth., which exhibits cytotoxic activity against HL-60 leukemia cells. The process according to the solution includes the following steps: a) preparing the raw material from the bark of the medicinal plant *Euphorbia hirta*; b) extracting the powdered raw material with 70% ethanol to obtain the ethanol extract labeled VT-E; c) dissolving the VT-E extract in hot water to obtain a liquid mixture; d) partition extraction with n-hexane to obtain the n-hexane extract labeled VT-H; e) partition extraction with dichloromethane to obtain the dichloromethane extract labeled VT-DCM; f) partition extraction with ethyl acetate to obtain the ethyl acetate extract labeled VT-EA. g) Isolating the fraction containing kaempferol-3-O-rhamnoside from the VT-EA extract using silica gel column chromatography to obtain the fraction labeled VT-EA-6; h) Purifying the VT-EA-6 fraction using column chromatography to obtain the fraction labeled VT-EA-6-3; i) Purifying the VT-EA-6-3 fraction using silica gel column chromatography to obtain the kaempferol-3-O-rhamnoside compound with formula (1). The compound kaempferol-3-O-rhamnoside obtained by the utility solution procedure exhibited significant cytotoxic activity against HL60 leukemia cell line under in vitro conditions.

Use of a compound of general formula (A) which is a CFS-IR kinase inhibitor or a pharmaceutically acceptable salt thereof in the preparation of medicaments for treating diseases related to CSF-1R kinase signal transduction pathway or medicaments for regulating immunization. In vivo and in vitro studies show that the compound can significantly inhibit CSF-IR kinase activity; significantly inhibits the proliferation of a CSF-1 / CSF-1R-driven mouse myeloid leukemia cell line, inhibits the survival of macrophages induced by CSF-1 and reverses M2 polarization phenotype of macrophages, and has an effect superior to that of the marketed medicament Pexidartinib. In a TAM enriched tumor model (MC38 model), the compound significantly antagonizes the tumor immunosuppressive microenvironment and exhibits significant anti-tumor efficacy. The compound has inhibitory effects on tumors that are not sensitive to immune checkpoint drugs, and can enhance the efficacy of immune checkpoint drugs, and has good clinical application prospects.

The invention discloses an application of an anti-malarial drug primaquine phosphate in preparation of drugs for treating BCR-ABL positive leukemia and breast cancer and a drug combination composition, and discovers that the anti-malarial drug primaquine phosphate has obvious effects of resisting BCR-ABL + leukemia and breast cancer, and has obvious anti-BCR-ABL + leukemia and breast cancer in the cellular level. The PRQ can significantly inhibit the growth of a BCR-ABL + leukemia cell line and an imatinib drug-resistant BCR-ABL + leukemia cell line, significantly inhibit the growth of breast cancer cells and induce ferroptosis of the breast cancer cells, and further researches find that the PRQ can degrade wild or mutant BCR-ABL proteins in a targeted manner. At the patient level, the PRQ is found to be capable of inhibiting the formation ability of primary cell colonies of wild-type or mutant patients with the BCR-ABL + leukemia, and at the animal level, the PRQ is found to have an obvious inhibiting effect on the progress of the BCR-ABL + leukemia.

The application belongs to the technical field of biological medicine, and particularly relates to application of circular RNA (circRNA) CIRC8341 in leukemia. The application proves that the circular RNA CIRC8341 is stably present in leukemia cells and is generally highly expressed in leukemia cell lines through RNase R experiments and qRT-PCR experiments. Meanwhile, it is found through research that targeting CIRC8341 can significantly inhibit the growth of leukemia cells; the test results of a mouse leukemia model show that knocking down the expression of CIRC8341 can significantly inhibit the survival of leukemia cells and significantly prolong the survival cycle of model mice. The above results show that CIRC8341 can play a role in leukemia as a therapeutic target.